Article

Former Alcon executive joins Iridex as CEO

Mountain View, CA—Barry G. Caldwell, a former vice president and general manager with Alcon's U.S. surgical division and vice president of Alcon Canada, has joined Iridex Corp. as president and chief executive officer.

Mountain View, CA-Barry G. Caldwell, a former vice president and general manager with Alcon's U.S. surgical division and vice president of Alcon Canada, has joined Iridex Corp. as president and chief executive officer.

Caldwell, who has spent more than 30 years in management roles within the ophthalmic industry, succeeds Theodore A. Boutacoff, 58, who was elected chairman of the Iridex board of directors earlier this year. Boutacoff has served as president and chief executive officer since 1989.

Caldwell, who also was elected to the board, spent more than 20 years with Alcon Laboratories. He worked as vice president of sales, marketing, and technical services for Alcon's surgical instrumentation unit, where he led a staff of 250, and later as vice president and general manager of that unit. As vice president of Alcon Canada, he guided its consumer business to a leading market share position.

Under his leadership, the surgical segment grew into a $600 million division and market share significantly increased. Caldwell also created and executed a long-term corporate development and acquisition strategy for Alcon and was responsible for managing the company's relationships with legislative and regulatory agencies.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.